About Hyloris Pharmaceuticals SA

Company Description

We are a specialty biopharma company committed to bringing innovative, value-added medicines that address the needs of underserved patient populations.

We apply our knowhow and technological innovations to existing pharmaceuticals to unlock their hidden potential and address unmet medical needs. We have built a broad proprietary pipeline of complex value-added products with potential to offer significant advantages over currently available alternatives.

Today, we have two, partnered commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic® IV, a novel, dual mode-of-action non-opioid analgesic for the treatment of post-operative pain.

Our development strategy of reformulating and repurposing approved pharmaceuticals primarily utilises the 505(b)(2) regulatory pathway in the U.S. and similar pathways in other countries, which are specifically designed for pharmaceutical agents for which the safety and efficacy have already been established.

Year founded


Served area



Boulevard Patience et Beaujonc 3/1, 4000 Rocourt, Liège – Belgium

Shareholder information

Shares outstanding



June 29, 2020

Stock exchange(s)

Euronext Brussels



Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.